Aquestive Therapeutics, Inc. Segments Disclosure
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Revenues | $ | 44,545 | $ | 57,561 | |||||||
| Costs and expenses: | |||||||||||
Total Manufacture and Supply Expenses | 18,555 | 17,872 | |||||||||
| R&D Project expenses: | |||||||||||
Anaphylm project expenses | 5,815 | 9,471 | |||||||||
| AQST-108 project expenses | 497 | 786 | |||||||||
Libervant project expenses | — | 2 | |||||||||
| R&D other expenses: | |||||||||||
Personnel costs1 | 8,650 | 7,724 | |||||||||
Other2 | 2,230 | 2,297 | |||||||||
Total Research and Development Expenses | 17,192 | 20,280 | |||||||||
Selling expenses: | |||||||||||
Personnel costs3 | 3,719 | 2,382 | |||||||||
Other4 | 14,765 | 5,164 | |||||||||
Total Selling expenses | 18,484 | 7,546 | |||||||||
General & Administrative expenses: | |||||||||||
Personnel costs5 | 19,823 | 21,064 | |||||||||
Other6 | 41,542 | 21,570 | |||||||||
Total General and Administrative Expenses | 61,365 | 42,634 | |||||||||
Total Selling, General and Administrative Expenses | 79,849 | 50,180 | |||||||||
| Total costs and expenses | 115,596 | 88,332 | |||||||||
| Loss from operations | (71,051) | (30,771) | |||||||||
| Other income/(expenses), net | (12,733) | (13,380) | |||||||||
| Net loss before income taxes | (83,784) | (44,151) | |||||||||
| Income taxes benefit | — | 14 | |||||||||
| Net loss | $ | (83,784) | $ | (44,137) | |||||||
| Comprehensive loss | $ | (83,784) | $ | (44,137) | |||||||
1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance | ||||||||||||||
| 2 - Other R&D expenses include preclinical, consulting, maintenance, and testing fees | ||||||||||||||
| 3 - Selling Personnel costs include payroll expenses, share-based compensation expenses and severance | ||||||||||||||
4 - Other Selling expenses include commercialization and other related expenses | ||||||||||||||
5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance | ||||||||||||||
| 6 - Other General and Administrative expenses include legal/patent fees, legal expenditures, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 4, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.